Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
暂无分享,去创建一个
R. Phillips | D. Cooper | C. Willberg | J. Weber | A. Kelleher | M. Schechter | A. Babiker | J. Frater | E. Hamlyn | N. Robinson | S. Fidler | G. Tambussi | M. Fisher | M. Pace | K. Koelsch | S. Kinloch | Helen L. Brown | J. Meyerowitz | J. Hurst | M. Hoffmann | J. Thornhill | James P. Williams | H. Brown | R. Phillips
[1] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[2] C. Qiu,et al. The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects , 2015, The Journal of Immunology.
[3] L. Rong,et al. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. , 2014, Journal of theoretical biology.
[4] M. Carrington,et al. HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.
[5] L. Weinberger,et al. Stochastic variability in HIV affects viral eradication , 2014, Proceedings of the National Academy of Sciences.
[6] John Frater,et al. Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’ , 2014, Journal of virological methods.
[7] J. Miro,et al. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression , 2014, AIDS.
[8] R. Phillips,et al. HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.
[9] Mardge H. Cohen,et al. Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals , 2014, AIDS.
[10] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[11] J. Kappes,et al. High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse , 2013, Journal of Virology.
[12] P. Kaleebu,et al. Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy , 2013, PloS one.
[13] E. Shankar,et al. Molecular signatures of T-cell inhibition in HIV-1 infection , 2013, Retrovirology.
[14] Brigitte Autran,et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.
[15] Steve Kaye,et al. Short-course antiretroviral therapy in primary HIV infection. , 2013, The New England journal of medicine.
[16] B. Walker,et al. HIV and HLA class I: an evolving relationship. , 2012, Immunity.
[17] M. Rosińska,et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.
[18] C. Rouzioux,et al. Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.
[19] S. Lewin,et al. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells , 2011, Retrovirology.
[20] Daniel Coombs,et al. A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients , 2011, PLoS Comput. Biol..
[21] T. Okazaki,et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice , 2011, The Journal of experimental medicine.
[22] Jack T Stapleton,et al. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.
[23] B. Berkhout,et al. Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome , 2009, PloS one.
[24] Jianqing J. Yu,et al. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. , 2009, Methods.
[25] R. Kaul,et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection , 2008, The Journal of experimental medicine.
[26] B. Berkhout,et al. Highly Sensitive Methods Based on Seminested Real-Time Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 Unspliced and Multiply Spliced RNA and Proviral DNA , 2008, Journal of Clinical Microbiology.
[27] Jacques Fellay,et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.
[28] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[29] M. Friendly. Corrgrams , 2002 .
[30] T. Jaakkola,et al. Fast optimal leaf ordering for hierarchical clustering , 2001, ISMB.
[31] D. Ho,et al. Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.
[32] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[33] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[34] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[35] T. May. An Evolving Relationship , 1990 .
[36] David Heckerman,et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.
[37] S. Hammer,et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. , 2003, The Journal of infectious diseases.